Bank of America Securities Reiterates Buy Rating for Novo Nordisk with DKK550 Price Target
PorAinvest
lunes, 7 de julio de 2025, 8:56 am ET1 min de lectura
BAC--
Bank of America Securities analyst Sachin Jain maintained a Buy rating for Novo Nordisk (NVO) on July 1, with a price target of DKK550.00. The company's shares closed at DKK444.71 on the previous day. This rating aligns with the broader analyst consensus, which is a Moderate Buy, with an average price target of DKK629.17, representing a 41.48% upside [3].
Novo Nordisk, a Danish pharmaceutical company with a market cap of DKK1943.9 billion, operates in two primary business segments: Diabetes and Obesity Care, and Rare Disease. The company reported a consolidated turnover of approximately $44 billion on a TTM basis [4]. The company's current P/E ratio is 18.61, indicating its valuation relative to earnings [3].
The analyst consensus on Novo Nordisk is a Moderate Buy, with a price target of DKK629.17, indicating a significant upside potential. UBS also maintained a Buy rating on the stock with a DKK700.00 price target [3]. Despite the positive analyst ratings, corporate insider sentiment has been negative, with 31 insiders selling their shares in the past quarter [3].
Novo Nordisk has been in the news recently for its plans to upgrade its factory in Anagni, Italy, with a planned investment of €2 billion ($2.34 billion). The Italian government has designated the project as being of "pre-eminent strategic interest," allowing for fast-tracking of approval procedures [2].
References:
[1] https://www.marketscreener.com/quote/stock/NOVO-NORDISK-A-S-1412980/consensus/
[2] https://www.investing.com/news/stock-market-news/italy-appoints-commissioner-to-accelerate-novo-nordisk-factory-investment-93CH-4124747
[3] https://www.theglobeandmail.com/investing/markets/stocks/NVO/pressreleases/33238912/bank-of-america-securities-sticks-to-its-buy-rating-for-novo-nordisk-0qiu/
[4] https://seekingalpha.com/article/4799487-novo-nordisks-sell-off-has-gone-too-far?source=affiliate_program:stockanalysis.com&utm_medium=affiliate&utm_source=stockanalysis.com&affid=858&oid=16&transaction=2c281206c3a94273909240dabb97b22f
NVO--
UBS--
Bank of America Securities analyst Sachin Jain maintained a Buy rating and DKK550 price target for Novo Nordisk. The analyst consensus is a Moderate Buy with an average price target of DKK629.17, representing a 41.48% upside. Novo Nordisk's market cap is DKK1943.9B and has a P/E ratio of 18.61. Corporate insider sentiment is negative, with 31 insiders selling their shares in the past quarter.
July 02, 2025Bank of America Securities analyst Sachin Jain maintained a Buy rating for Novo Nordisk (NVO) on July 1, with a price target of DKK550.00. The company's shares closed at DKK444.71 on the previous day. This rating aligns with the broader analyst consensus, which is a Moderate Buy, with an average price target of DKK629.17, representing a 41.48% upside [3].
Novo Nordisk, a Danish pharmaceutical company with a market cap of DKK1943.9 billion, operates in two primary business segments: Diabetes and Obesity Care, and Rare Disease. The company reported a consolidated turnover of approximately $44 billion on a TTM basis [4]. The company's current P/E ratio is 18.61, indicating its valuation relative to earnings [3].
The analyst consensus on Novo Nordisk is a Moderate Buy, with a price target of DKK629.17, indicating a significant upside potential. UBS also maintained a Buy rating on the stock with a DKK700.00 price target [3]. Despite the positive analyst ratings, corporate insider sentiment has been negative, with 31 insiders selling their shares in the past quarter [3].
Novo Nordisk has been in the news recently for its plans to upgrade its factory in Anagni, Italy, with a planned investment of €2 billion ($2.34 billion). The Italian government has designated the project as being of "pre-eminent strategic interest," allowing for fast-tracking of approval procedures [2].
References:
[1] https://www.marketscreener.com/quote/stock/NOVO-NORDISK-A-S-1412980/consensus/
[2] https://www.investing.com/news/stock-market-news/italy-appoints-commissioner-to-accelerate-novo-nordisk-factory-investment-93CH-4124747
[3] https://www.theglobeandmail.com/investing/markets/stocks/NVO/pressreleases/33238912/bank-of-america-securities-sticks-to-its-buy-rating-for-novo-nordisk-0qiu/
[4] https://seekingalpha.com/article/4799487-novo-nordisks-sell-off-has-gone-too-far?source=affiliate_program:stockanalysis.com&utm_medium=affiliate&utm_source=stockanalysis.com&affid=858&oid=16&transaction=2c281206c3a94273909240dabb97b22f

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios